What is the modified FOLFOX‑6 (folinic acid, fluorouracil, oxaliplatin) chemotherapy protocol?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Modified FOLFOX-6 Protocol

Modified FOLFOX-6 (mFOLFOX6) is a chemotherapy regimen consisting of oxaliplatin 85 mg/m² IV over 2 hours, leucovorin 400 mg/m² IV over 2 hours (given concurrently with oxaliplatin in separate bags), followed by fluorouracil 400 mg/m² IV bolus, then fluorouracil 2,400 mg/m² as a continuous infusion over 46 hours, repeated every 14 days. 1

Regimen Components and Administration

The protocol is administered on a 2-week cycle:

Day 1:

  • Oxaliplatin 85 mg/m² IV infusion over 2 hours
  • Leucovorin 400 mg/m² IV infusion over 2 hours (simultaneously with oxaliplatin via Y-connector)
  • Fluorouracil 400 mg/m² IV bolus immediately after
  • Fluorouracil 2,400 mg/m² continuous IV infusion over 46 hours (using pump device)

Day 2:

  • No oxaliplatin administered
  • The fluorouracil infusion continues from Day 1 2, 1

Clinical Indications

mFOLFOX6 is FDA-approved for:

  • Adjuvant treatment of stage III colon cancer after complete resection (continue for up to 12 cycles or until unacceptable toxicity)
  • Advanced/metastatic colorectal cancer (continue until disease progression or unacceptable toxicity) 1

For adjuvant stage III colon cancer, discontinue oxaliplatin after 3 months (6 cycles) while continuing fluorouracil/leucovorin to complete 6 months total treatment in low-risk patients (T1-3, N1). For high-risk patients (T4 and/or N2), complete the full 6 months of oxaliplatin-containing therapy. 3, 2

Key Management Considerations

Oxaliplatin-Related Neuropathy

Discontinue oxaliplatin from mFOLFOX6 after 3 months of therapy, or sooner for unacceptable neurotoxicity, while maintaining fluorouracil/leucovorin for the entire 6 months or until progression. 3

Critical patient instructions:

  • Avoid all cold exposure (cold drinks, ice cubes, cold objects, cold outdoor temperatures)
  • Cover skin when going outdoors in cold weather
  • Never apply ice or ice packs to the body
  • Cold exposure can trigger or worsen acute neuropathy symptoms 1

Hematologic Monitoring

Delay treatment until neutrophils ≥1.5 × 10⁹/L and platelets ≥75 × 10⁹/L. Withhold for sepsis or septic shock. Dose reduce after recovery from grade 4 neutropenia, febrile neutropenia, or grade 3-4 thrombocytopenia. 1

Hypersensitivity Risk

Permanently discontinue oxaliplatin immediately for any hypersensitivity reaction, including anaphylaxis, which can occur within minutes of administration and during any cycle. This is a black box warning. 1

Important Contraindications and Precautions

  • Contraindicated in patients with prior hypersensitivity to oxaliplatin or platinum-based drugs
  • Monitor liver function tests at baseline, before each cycle, and as clinically indicated
  • Avoid in patients with congenital long QT syndrome; monitor ECGs in patients with heart failure or arrhythmias
  • Can cause Posterior Reversible Encephalopathy Syndrome (PRES) - permanently discontinue if this occurs 1

Efficacy Data

In the NCCN guidelines, FOLFOX and CAPEOX are considered interchangeable for metastatic colorectal cancer, with panel consensus supporting their equivalent efficacy. 3 The regimen demonstrates objective response rates of 53-81% in various gastrointestinal malignancies depending on disease setting and prior treatment exposure. 4, 5

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.